Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6.5 USD | +3.83% | +15.66% | +43.81% |
Mar. 15 | Transcript : ProPhase Labs, Inc., 2023 Earnings Call, Mar 15, 2024 | |
Mar. 15 | ProPhase Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Business Summary
Number of employees: 129
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Diagnostic Services
88.3
%
| 69 | 86.7 % | 108 | 88.3 % | +58.01% |
Consumer Products
11.7
%
| 10 | 13.3 % | 14 | 11.7 % | +36.58% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 79 | 100.0 % | 123 | 100.0 % | +55.17% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ted Karkus
CEO | Chief Executive Officer | 64 | 09-06-14 |
Chief Operating Officer | 50 | Dec. 31 | |
Robert Morse
AUD | Comptroller/Controller/Auditor | 49 | 22-06-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Louis Gleckel
BRD | Director/Board Member | 68 | 09-05-31 |
Ted Karkus
CEO | Chief Executive Officer | 64 | 09-06-14 |
Jason Barr
BRD | Director/Board Member | 44 | 15-05-31 |
Warren Hirsch
BRD | Director/Board Member | 66 | 19-05-21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 36,985,996 | 14,076,427 ( 38.06 %) | 18,940,967 ( 51.21 %) | 38.06 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
LANTERN PHARMA INC. 5.81% | 631,195 | 5.81% | 3,036,048 $ |
Company contact information
Sector
Sales per Business
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+43.81% | 113M | |
+6.08% | 7.7B | |
-1.30% | 7.15B | |
+1.75% | 5.84B | |
-2.11% | 3.96B | |
-14.29% | 3.38B | |
-5.45% | 1.25B | |
-9.31% | 929M | |
+4.04% | 914M | |
-15.54% | 812M |
- Stock
- Equities
- Stock ProPhase Labs, Inc. - Nasdaq
- Company ProPhase Labs, Inc.